Vaccine Adverse Event Reporting System

Vaccine Adverse Event Reporting System
Name	Vaccine Adverse Event Reporting System
Established	1990
Jurisdiction	United States
Parent agency	Food and Drug Administration; Centers for Disease Control and Prevention

Vaccine Adverse Event Reporting System

The Vaccine Adverse Event Reporting System is a national passive surveillance program established to monitor post-vaccination adverse events in the United States, operated jointly by the Food and Drug Administration and the Centers for Disease Control and Prevention. It collects reports from healthcare professionals, manufacturers, and the public to detect safety signals associated with immunizations such as those distributed by Pfizer, Moderna, Johnson & Johnson, and historical programs like the Vaccination Program (United States). The system interfaces with other public health initiatives including the National Vaccine Program Office, the Advisory Committee on Immunization Practices, and global organizations like the World Health Organization.

Overview

The system functions as a national spontaneous reporting mechanism to identify potential vaccine safety issues by aggregating individual case reports from diverse sources including clinicians at Mayo Clinic, pharmacists at Walgreens Boots Alliance, and manufacturers such as Merck & Co. and Sanofi. It aids regulatory decision-making by providing data for agencies like the Food and Drug Administration and advisory bodies such as the Vaccine Safety Datalink and the Institute of Medicine, informing immunization guidelines from the Advisory Committee on Immunization Practices. Interaction with academic centers like Johns Hopkins University, Harvard Medical School, and Stanford University supports epidemiological analyses.

History and Development

The program was created in 1990 after legislative and regulatory discussions involving the Omnibus Budget Reconciliation Act of 1990 and input from stakeholders including the American Medical Association, vaccine manufacturers like Wyeth and GlaxoSmithKline, and consumer advocates. Early development included collaboration with the National Institutes of Health, researchers at Centers for Disease Control and Prevention, and legal frameworks influenced by cases heard at the United States Court of Federal Claims. Subsequent milestones included integration with electronic reporting systems used by institutions such as Kaiser Permanente and enhancements prompted by vaccine safety reviews following immunization campaigns for H1N1 influenza, Human papillomavirus vaccine rollouts, and the COVID-19 vaccination effort involving Operation Warp Speed.

Operation and Data Collection

Operationally, the system receives reports via online portals and paper forms submitted by entities including clinicians at Cleveland Clinic, hospitals in the Veterans Health Administration, and manufacturers like AstraZeneca. Reports encompass event narratives, patient demographics, product information, and lot numbers tied to distribution networks managed by McKesson Corporation and pharmacies like CVS Health. Data flow supports signal detection algorithms used by analysts with ties to institutions such as Yale School of Public Health and is complemented by active surveillance projects including the Vaccine Safety Datalink and international collaborations with the European Medicines Agency.

Reporting Process and Eligibility

Anyone can submit a report, including healthcare providers at institutions like Mount Sinai Health System, vaccine manufacturers such as Sanofi, and members of the public connected with advocacy groups like Every Child By Two. Mandatory reporting requirements apply to manufacturers under regulations enforced by the Food and Drug Administration and to certain providers under program policies linked to immunization programs in jurisdictions like New York (state) and California. The process captures details necessary for follow-up by public health officials from the Centers for Disease Control and Prevention and legal counsel from the Department of Health and Human Services when events meet criteria established in policy documents and relevant statutes.

Data Analysis, Access, and Limitations

Analysts from agencies including the Food and Drug Administration and researchers at George Washington University use the database for pharmacovigilance, employing statistical disproportionality methods and clinical review in partnership with academic centers like Columbia University and University of Pennsylvania. Public access tools provide aggregated summary data for stakeholders, media outlets such as The New York Times, and advocacy organizations like the National Vaccine Information Center, but the dataset has inherent limitations: underreporting, reporting biases noted by institutions like Cochrane, variable data quality highlighted by Institute of Medicine reports, and inability to establish causality without confirmatory studies from networks like the Clinical Immunization Safety Assessment Project.

Controversies and Criticisms

The program has faced scrutiny from legislative bodies such as the United States Congress, advocacy groups including Every Child By Two and National Vaccine Information Center, and scholars at Brown University regarding transparency, data interpretation, and media reporting practices by outlets like Fox News and CNN. Critics point to misuse of raw reports to infer causation, concerns echoed in analyses by JAMA and The Lancet, and debates over data access and redaction that involved regulators at the Food and Drug Administration and legal challenges in federal courts. Reforms have been proposed by panels organized by the National Academies of Sciences, Engineering, and Medicine.

Impact on Public Health Policy

Data from the system have influenced vaccine policy decisions by the Advisory Committee on Immunization Practices, regulatory actions by the Food and Drug Administration, and compensation outcomes under the National Vaccine Injury Compensation Program. Analyses contributed to updated guidance during outbreaks managed by agencies like the Centers for Disease Control and Prevention and informed communication strategies used by public health offices in states such as California and Texas. Collaborative research with academic partners including University of Michigan and Emory University continues to refine risk-benefit assessments that shape immunization schedules and emergency use decisions in contexts like pandemic response coordinated with Operation Warp Speed.

Category:Pharmacovigilance